インドでのキイトルーダ療法に最適なクリニックと費用をご発見ください2026

Keytruda is an immunotherapy medication that reboots the immune system to identify and kill cancer cells. Unlike chemotherapy, this monoclonal antibody blocks the PD-1 pathway, preventing tumors from hiding and allowing T cells to naturally destroy advanced cancers like melanoma or lung carcinoma.

• Mechanism of action: It blocks PD-1 receptors so T cells can recognize and attack cancerous tumors.
• Treatment frequency: Administered via intravenous infusion every 3 or 6 weeks in clinical settings.
• Targeted cancers: Effectively treats melanoma, non-small cell lung cancer, and MSI-H positive solid tumors.
• Side effects: Potential immune-mediated inflammation affecting organs like the lungs, colon, or liver.

Bookimed Expert Insight: India has become a global hub for Keytruda due to high-volume expertise at centers like HCG Manavata Cancer Centre, where teams have performed over 50,000 surgeries. While US infusions average $21,500, Indian clinics offer the same immunotherapy starting at $3,500, saving patients up to 77%.

Patient Consensus: Patients emphasize that immunotherapy feels different from chemotherapy because it revs up immunity rather than poisoning cells. many report that monitoring biomarkers like PD-L1 was crucial for predicting their individual success with the drug.

Keytruda is approved in India by the Drug Controller General of India (DCGI). It is cleared for multiple cancer indications including non-small cell lung cancer, melanoma, and triple-negative breast cancer. Treatment is available at JCI-accredited facilities like Artemis Hospitals and Apollo Hospital Indraprastha.

• Approved indicators: DCGI covers renal cell carcinoma, cervical cancer, and esophageal cancer cases.
• Prescription requirements: Dispensing requires a valid prescription from a board-certified oncologist in India.
• Typical pricing: Immunotherapy with Keytruda in India ranges from $3,500 to $6,200.
• Cost savings: Patients save up to 77% compared to average US prices of $21,500.

Bookimed Expert Insight: Success with Keytruda in India often depends on doctor experience with immunotherapy protocols. Dr. Shruti Kate at HCG Manavata Cancer Centre specializes specifically in these treatments. Many top Indian clinics now also use IBM Watson AI platforms to verify treatment compatibility.

Patient Consensus: Success depends on confirming drug availability for your specific cancer subtype before traveling. Patients highly value the cost difference but recommend asking about immune-related side effect monitoring plans.